NCT03487913 - The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

December 2, 2019

Study Completion Date

February 11, 2020

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

DRUG

Lixivaptan

Oral vasopressin V2 receptor antagonist

Trial Locations (13)

Palladio Biosciences Clinical Site, Laurelton

Palladio Biosciences Clinical Site, Indiana

Palladio Biosciences Clinical Site, Baltimore

Palladio Biosciences Clinical Site, Jacksonville

Palladio Biosciences Clinical Site, Miami

Palladio Biosciences Clinical Site, Palmetto Bay

Palladio Biosciences Clinical Site, Miami

Palladio Biosciences Clinical Site, Tampa

Palladio Biosciences Clinical Site, Rochester

Palladio Biosciences Clinical Site, Kansas City

Palladio Biosciences Clinical Site, Nashville

Palladio Biosciences Clinical Site, Salt Lake City

Palladio Biosciences Clinical Site, Los Angeles